Up to now, pooled Human Platelet Lysate (HPL) products contain plasmatic coagulation factors such as fibrinogen. This is because HPL is produced from lysed human platelets which are part of the wound healing cascade. To prevent clot formation in cell culture, anticoagulants need to be added.
It is possible to reduce the fibrinogen content of HPL by using different manufacturing processes. Due to the simplified handling, fibrinogen-depleted products make it even easier to switch from serum-containing to serum-free cell culture media.
The use of fibrinogen-depleted Human Platelet Lysate eliminates the need for anticoagulant administration.